ABPI appoints new chief executive

11 February 2016
abpi-big-1

The UK's Association of the British Pharmaceutical Industry (ABPI) has named Mike Thompson as its new chief executive.

Mr Thompson, who will take up his new role on March 1, leaves GlaxoSmithKline where he has held several senior positions during 20 years at the company. His most recent position was as senior vice president of global commercial strategy and platforms.

Prior to joining GSK, Mr Thompson worked for Unilever in its food and toiletries division.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical